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Abstract
Background: Anti-glycyl-tRNA synthetase (anti-EJ) antibody is occasionally positive in patients with interstitial lung
disease (ILD). We aimed to define the clinical, radiological and pathological features of patients with anti-EJ
antibody-positive ILD (EJ-ILD).
Methods: We retrospectively analyzed the medical records of 12 consecutive patients with EJ-ILD who underwent
surgical lung biopsy.
Results: The median follow-up time was 74 months (range, 17–115 months). The median age was 62 years
(range, 47–75 years). Seven of 12 patients were female. Eight patients presented with acute onset. Six patients
eventually developed polymyositis/dermatomyositis. On high-resolution computed tomography, consolidation
and volume loss were predominantly observed in the middle or lower lung zone. Nine patients presented
pathologically nonspecific interstitial pneumonia with organizing pneumonia, alveolar epithelial injury and
prominent interstitial cellular infiltrations whereas the other three patients were diagnosed with unclassifiable
interstitial pneumonia. Although all patients but one improved with the initial immunosuppressive therapy,
five patients relapsed. When ILD relapsed, four of the five patients were treated with corticosteroid monotherapy.
Four of the six patients without relapse have been continuously treated with combination therapy of corticosteroid
and immunosuppressant.
Conclusions: Patients with EJ-ILD often had acute onset of ILD with lower lung-predominant shadows and
pathologically nonspecific interstitial pneumonia or unclassifiable interstitial pneumonia with acute inflammatory
findings. Although the disease responded well to the initial treatment, relapse was frequent. Because of the diversity
of the clinical courses, combination therapy of corticosteroid and immunosuppressant should be on the list of
options to prevent relapse of EJ-ILD.
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Background
Interstitial lung disease (ILD) is caused by various etiolo-
gies including collagen vascular disease, drug induced and
inhalation exposure. Patients with ILD often have collagen
vascular disease-related autoantibodies even when they do
not fulfill the diagnostic criteria for any collagen vascular
diseases [1]. In 2015, the “European Respiratory Society
(ERS)/American Thoracic Society (ATS) Task Force on
Undifferentiated Forms of Connective Tissue Disease-
associated Interstitial Lung Disease” proposes the term
“interstitial pneumonia with autoimmune features” (IPAF)
and offers classification criteria organized around the
presence of a combination of features from three domains:
a clinical domain, a serologic domain and a morphologic
domain [2]. Recent report showed autoantibodies against
aminoacyl-tRNA synthetase (ARS) have been found to be
highly specific for myositis and to associate with compli-
cating ILD, arthritis, Raynaud’s phenomenon, mechanic’s
hand and fever. Ten anti-ARS antibodies have been identi-
fied: anti-Jo-1, EJ, PL-7, PL-12, OJ, KS, Zo, SC, JS and YRS
antibodies [3, 4].
Anti-ARS antibodies are positive in 20%–35% of pa-
tients with polymyositis/dermatomyositis (PM/DM) [3, 5].
Among patients with PM/DM, anti-Jo-1 antibody is the
most common (15%–30%) while others are seen in less
than 10% [6]. Although, anti-EJ antibody, which is against
glycyl-tRNA synthetase [7], is generally less common
than anti-Jo-1 antibody, it has a higher prevalence than
anti-Jo-1 antibody in some case series of patients with ILD
positive of anti-ARS antibodies (ARS-ILD) [8, 9]. Mean-
while, over 90% of patients with positive-anti-ARS anti-
bodies show ILD complications [10].
On computed tomography (CT), patients with ARS-ILD
often have radiologically traction bronchiectasis, conso-
lidation and volume loss predominantly in the lower lung
zones [9, 11, 12]. Histopathological patterns are reported
as nonspecific interstitial pneumonia (NSIP), usual inter-
stitial pneumonia (UIP), acute lung injury (ALI) or diffuse
alveolar damage (DAD) [9, 11–13]. Although clinical course
of treatment response to ARS-ILD is reportedly good,
relapses are frequent [14].
However, there are only a few reports describing the
clinical features of patients with ILD with positive-anti-
EJ antibody (EJ-ILD) [15, 16]. The aim of this retrospect-
ive study was to define the clinical, radiological and patho-




We retrospectively analyzed the medical records of 12
consecutive patients with EJ-ILD who underwent surgical
lung biopsy at Kanagawa Cardiovascular and Respiratory
Center between March 2005 and April 2013 and were
subsequently followed up for over one year. Anti-ARS
antibodies were detected with an immunoprecipitation
assay at Tokai University School of Medicine as previously
described method [17].
Clinical information
We obtained the clinical presentations, physical findings,
laboratory findings and pulmonary function tests at the
initial visit from patients’ medical records. The diagnosis
of PM/DM was based on Bohan and Peter’s criteria [18].
Patients satisfying at least two of the five of the criteria
were diagnosed with PM/DM. IPAF and anti-synthetase
syndrome were diagnosed according to each proposed cri-
teria [2, 19]. The onset of EJ-ILD was divided into two
types according to the time from the initial symptoms to
the initial hospital visit: 1) within three months (acute
onset) and 2) over three months (chronic onset). The
Table 1 Definition of the initial response to treatment




Improved Improved Improved Deteriorated
Stable Improved Stable Deteriorated
Deteriorated Improved Deteriorated Deteriorated
a“Improved” meant at least 10% increase in forced vital capacity % predicted
(%FVC) or at least 15% increase in diffusing capacity of the lung for carbon
monoxide % predicted (%DLCO). Stable was defined as within 10% change of
%FVC and within 15% change of %DLCO. “Deteriorated” meant over 10%
decrease in %FVC or over 15% decrease in %DLCO.
Table 2 Clinical characteristics and diagnosis of 12 patients
Clinical characteristics n = 12
Male/female 5/7
Age at initial visit [years] 62 (47–75)
Acute onset/chronic onset 8/4
Smoking status (current or former/never smoker) 6/6
Serological findings (reference value) n = 12
CK [U/L] (62–287) 140 (17–672)
LDH [U/L] (70–139) 252 (212–337)
ESR [mm/h] (2–10) 38 (17–116)
CRP [mg/dl] (0–0.1) 0.63 (0.03–1.79)
KL-6 [U/ml] (0–500) 991 (514–3208)
SP-D [ng/ml] (0–110) 232.3 (56.1–723.1)
PaO2 [Torr] (74–108) 71.5 (53.0–84.5)
Pulmonary functions n = 11
FVC % predicted [%] 71.5 (42.4–86.1)
DLCO % predicted [%] 66.1 (56.0–112.2)
Data are presented as n, or median (range)
CK: Creatine kinase, LDH: Lactate dehydrogenase, ESR: Erythrocyte
sedimentation rate, CRP: C-reactive protein, KL-6: Klebs von den lungen-6,
SP-D: Surfactant protein D, PaO2: Arterial oxygen pressure, FVC: Forced vital
capacity, DLCO: Diffusion capacity for carbon monoxide
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Table 3 Clinical symptoms and physical findings related to IPAF and anti-synthetase syndrome
Patient
number










Muscular involvementb Distal digital tip
ulceration
CK level
1 IPAF/ASS + - - - - - - - - - 218
2 IPAF/ASS + + - - - + - - - - 136
3 IPAF/ASS + - - - - - - - - - 50
4 PMI + - - - - +c - - +c - 346E
5 IPAF/ASS + + - - - - - +c +c - 51
6 DMI + - + - +c - - +c - - 143
7 IPAF/ASS + + - - - - - +c +c - 17
8 PMI + - +c - +c +c +c - - - 513E
9 DMI - + +c - +c +c - - +c - 137
10 IPAF/ASS + + - - - - - + +c - 22
11 PMI + + - - - + + - +c - 230
12 PMS + + - - - - - + + - 672E
ainflammatory arthritis, or polyarticular morning joint stiffness > 60mins, bproximal muscular weakness, or myalgia, CK: creatine kinase, IPAF: interstitial pneumonia with autoimmune features, ASS: anti-synthetase















pattern of ILD onset in PM/DM patients was divided into
three types: 1) PM/DM was diagnosed at least three
months earlier than ILD (PM/DM-preceding type), 2) ILD
was diagnosed at least three months earlier than PM/DM
(ILD-preceding type), and 3) both occurred within three
months (simultaneous type) [14].
Radiological analysis
CT images before biopsy were obtained from all the 12
patients. All images were reviewed independently by two
experienced radiologists without any prior knowledge of
the clinical and pathological information.
To determine the distribution and extent of parenchymal
abnormalities, each lung was divided into three zones of
upper, middle and lower at the level of the carina and the
left inferior pulmonary vein. The following high resolution
CT (HRCT) findings were coded as present or absent in
each zone: reticulation, ground-glass opacity, consolidation,
bronchovascular thickening, traction bronchiectasis, hon-
eycombing, volume loss and emphysema. Radiological
assessment was based on those from previous studies
[9, 20]. Disagreements between the two radiologists were
resolved by consensus.
Pathological analysis
Biopsy was performed in all patients. Multiple specimens
mainly from the upper and lower lobes were obtained
from 11 of 12 patients. All the specimens were stained
with hematoxylin-eosin and Elastica van Gieson and were
reviewed independently by two experienced lung patholo-
gists who were not aware of the clinical and radiological
findings. Pathological patterns were diagnosed according
to the 2002 and 2013 ATS/ERS consensus classification of
the idiopathic interstitial pneumonias and 2008 ATS pro-
ject for idiopathic NSIP [21, 22].
The intensity and extent of the following pathological
features were semi-quantitatively graded as absent, mild,
moderate or severe: pleural fibrosis, pleuritis, lymphoid
follicles with germinal center, organizing pneumonia,
alveolar epithelial injury, interstitial cellular infiltration,
Table 4 HRCT findings of 12 patients
Findings Zones
Upper Middle Lower
Reticulation 11 12 12
Ground-glass opacity 11 12 12
Volume loss 2 9 12
Bronchovascular thickening 1 10 12
Traction bronchiectasis 5 11 11
Consolidation 4 11 11
Honeycombing 1 1 4
Emphysema 4 1 1
Upper: between apex and carina, Middle: between carina and left inferior
pulmonary vein, Lower: between inferior pulmonary vein and diaphragm
Fig. 1 HRCT images of patient #9 (76-years-old female, pathologically cellular NSIP). a The coronal image of the high-resolution computed
tomography (HRCT) showed bilateral volume loss and infiltration of lower lung field. b-d Transverse images of the HRCT. Consolidation
was observed from middle area to the subpleural area. Traction bronchiectasis was noted inside of consolidation. Reticulation and ground-glass
opacity were distributed around consolidation
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alveolar wall fibrosis, microscopic honeycombing, fibro-
blastic focus and collapse. Pathological assessment was
based on those from previous studies [13, 23, 24].
Disagreements between the two pathologists were dis-
cussed until consensus was reached.
Clinical course and treatment response
The clinical course and treatment response of EJ-ILD was
evaluated on the basis of the degree of changes in both
chest images and pulmonary functions. Two radiologists
evaluated the chest radiograph and/or HRCT. We graded
the changes in pulmonary functions according to the 2000
ATS/ERS consensus statement for idiopathic pulmonary
fibrosis (Table 1) [25]. In addition, the pattern of disease
behavior was divided into the following five types: 1)
reversible and selflimited, 2) reversible disease with risk of
progression, 3) stable with residual disease, 4) progressive,
irreversible disease with potential for stabilization, and 5)
progressive, irreversible disease despite therapy [22].
The initial response was assessed within six months
after the initiation of treatment. After the initial evaluation,
we assessed all chest radiographs and pulmonary functions
until the end of the follow-up period. The relapse of ILD
meant that the patients with deterioration needed to rein-
forced therapy for ILD.
Results
Clinical and laboratory findings of EJ-ILD
The summary of the clinical characteristics of the 12
patients is listed in Table 2. The patients included five
males and seven females with median age of 62 years
(range, 47–75 years) at the initial visit. Eight patients
presented acute onset.
At the disease onset, extra-pulmonary symptoms were
observed in only five patients, whereas all patients pre-
sented pulmonary symptoms. Only one patient was suffer-
ing from muscle weakness. Among six patients diagnosed
with IPAF and anti-synthetase syndrome, no patient had
skin involvement, and only one patient presented articular
symptoms. Two patients have not had extra-pulmonary
symptoms during entire follow-up period (Table 3).
Palmar telangiectasia was not assessed in all patients.
Creatine kinase levels were elevated in three patients
and lactate dehydrogenase levels were elevated in eight,
while all patients presented with the elevation of erythro-
cyte sedimentation rate, C-reactive protein, Klebs von den
Lungen-6 and surfactant protein-D levels. Electromyo-
graphy, muscle biopsy and magnetic resonance imagings
of muscle were performed in only two DM patients.
Specific autoantibodies other than anti-EJ antibody were
found in only one patient who had anti-SSA antibody at
the initial visit and was diagnosed with Sjögren’s syndrome
20 months after the diagnosis of EJ-ILD. Other patients
Fig. 2 Histopathology of surgical lung biopsies of patient #10 (cellular NSIP, 62-years-old female, right S9). a Low power view of the specimen
showed panlobular and homogeneous pattern including interstitial cellular infiltration and organization located in airspace or alveolar septa.
b, c High power view of an area of a square of (a) revealed focal membranous organization (arrows) observed in the alveolar duct.
Ill-defined border between the alveolar septa and alveolar lumina was seen. Staining: (a, b) Hematoxylin and eosin stain, (c) Elastica van
Gieson stein, Magnification: (a) 1×, (b, c) 10×
Table 5 Pathological diagnosis and findings
Diagnosis n = 12
cellular-NSIP 4
fibrosing-NSIP 5
unclassifiable interstitial pneumonia 3
Findings absent mild moderate severe
Organizing pneumonia 1 0 7 4
Alveolar epithelial injury 1 1 8 2
Interstitial cellular infiltration 0 4 5 3
Pleural fibrosis 0 4 8 0
Collapse 1 4 6 1
Alveolar wall fibrosis 3 4 4 1
Pleuritis 2 9 1 0
Lymphoid follicles with germinal
centers
6 6 0 0
Fibroblastic focus 8 2 2 0
Microscopic honeycombing 10 2 0 0
Organizing pneumonia involved less than 20% of the overall biopsy specimen
when the diagnosis was NSIP [21]. Alveolar epithelial injury was defined as
obscured border between alveolar septum and alveolar lumina with alveolar
epithelial shedding, intra-alveolar cellular infiltration and membranous
organization of the alveolar ducts and alveolar sac which meant focal
acute lung injury. Collapse meant atelectatic alveoli with intra-alveolar
fibrosis and agglutination of alveoli [35].
NSIP: nonspecific interstitial pneumonia
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had neither other autoantibodies nor the diagnosis of any
other collagen vascular diseases except for PM/DM.
Six patients were diagnosed with PM/DM during the
disease course and five of them were of the ILD-preceding
type. Others were all diagnosed with idiopathic interstitial
pneumonia and satisfied with the proposed criteria of
both IPAF and anti-synthetase syndrome.
Radiological findings
The HRCT findings are described in Table 4. All findings
were observed in both lobes. All but one patient presented
with reticulation and ground-glass opacity in all lobes. On
the other hand, volume loss, bronchovascular thickening,
traction bronchiectasis and consolidation were not com-
mon in the upper zone, but were predominant in the
middle or lower zones in almost all patients. Consolida-
tion was observed along the bronchus from the middle to
the subpleural area. Bronchiectasis was noted inside the
consolidation, which encompassed the lung architecture.
Reticulation and ground-glass opacity were distributed
around the consolidation. Typical HRCT images are
shown in Fig. 1.
Pathological findings
The median interval between the date of HRCT and biopsy
was 28 days (range, 1–85 days). Four patients were patho-
logically diagnosed with cellular NSIP (c-NSIP), five were
with fibrosing NSIP (f-NSIP), and three were with unclassi-
fiable interstitial pneumonia. Organizing pneumonia, alveo-
lar epithelial injury, interstitial cellular infiltration, pleural
fibrosis and collapse with moderate or severe grade were
observed in more than half of the patients (Table 5). Espe-
cially organizing pneumonia and alveolar epithelial injury
with moderate or severe grade were observed in two of four
patients with c-NSIP and in four of five f-NSIP patients.
Collapse was observed with moderate grade in one of four
patients with c-NSIP and with moderate or severe grade
in four of five with f-NSIP. Acute inflammatory findings
such as organizing pneumonia, alveolar epithelial injury
and interstitial cellular infiltration surrounded by collapse
with few hyaline membrane were more prominent in
unclassifiable interstitial pneumonia than in c-NSIP or
f-NSIP. Organizing pneumonia, alveolar epithelial injury
and collapse did not show diffuse but rather focal distribu-
tion. On the other hand, interstitial cellular infiltration
and pleural fibrosis were diffuse. Typical pathological
images are shown in Figs. 2, 3, 4.
Organizing pneumonia and alveolar epithelial injury
with moderate or severe grade were observed not only in
patients with acute onset but also in those with chronic
onset (Table 6).
Clinical course and treatment response
Details on the clinical courses and therapy of the 12
patients are shown in Table 7. Seven patients were treated
Fig. 4 Histopathology of surgical lung biopsies of patient #3 (unclassifiable interstitial pneumonia, 60-years-old male, right S2). The specimen showed
mixed fibrosing NSIP pattern and marked collapse with slight inflammatory cell infiltration. a, b Collapse with obliterative intraalveolar fibrosis and
disrupted alveolar elastic fibers were observed in the square. c Fragmented elastic fibers of the alveolar walls were seen in a higher magnification of
an area of a square of (b). Staining: (a) Hematoxylin and eosin stain, (b, c) Elastica van Gieson stein, Magnification: (a, b) 4×, (c) 10×
Fig. 3 Histopathology of surgical lung biopsies of patient #6 (fibrosing NSIP, 72-years-old female, left S9). a, b Uniform fibrosis of the same
age was observed diffusely in alveolar septa. Collapse was observed partially (square). c A higher magnification of an area of a square of
(b) showing intraluminal and mural incorporation fibrosis and condensed elastic fiber of the alveolar walls. Staining: (a) Hematoxylin and
eosin stain, (b, c) Elastica van Gieson stein, Magnification: (a, b) 4×, (c) 10×
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with combination therapy of corticosteroid and immuno-
suppressant as the initial treatment while five were given
corticosteroid monotherapy. The initial dose of corti-
costeroid was 0.5 mg/kg/day of prednisone in 11 patients.
The median time of prednisone dose tapering to 10 mg/
day was 91 days (range, 60–132 days).
The initial response was evaluated as improved in 11
of 12 patients. Radiological findings improved in 11 of
12 patients. Representative images of chest radiograph
are shown in Fig. 5, indicating the apparent lung volume
recovery. Pulmonary function, evaluated in 10 patients,
improved or stabilized in nine patients. Forced vital
capacity % predicted (%FVC) and/or diffusing capacity of
the lung for carbon monoxide % predicted (%DLCO)
increased immediately after the initial treatment and
remained almost stable between the initial evaluation
period (Fig. 6). On disease behavior, the type of reversible
disease with risk of progression were six patients, progres-
sive and irreversible disease with potential for stabilization
were five patients, and progressive and irreversible disease
despite therapy were one patient. Patient #12 was the only
patient who did not respond to the treatment and died
during the follow-up period.
The median follow-up time was 74 months (range, 17–
115 months). ILD relapsed in five of the 11 improved
patients after a median of 46 months (range, 8–78
months) from treatment initiation. Among the five re-
lapsed patients, four were on prednisone monotherapy
and four presented with acute onset of the disease. There
were few differences in the changes on chest radiograph
and pulmonary function test between the relapsed patients
and non-relapsed patients until relapse. However, upon
relapse, the loss of lung volume was clearly recognized
in chest radiograph, and both %FVC and %DLCO signi-
ficantly decreased. The addition of immunosuppressant
and/or the increase of the dose of corticosteroid reduced
the abnormal shadow and prevented deterioration of
%FVC and %DLCO (Fig. 7). On the other hand, four
of the six patients without relapse had continuously
been on combination therapy of corticosteroid and
immunosuppressant.
Discussion
We retrospectively evaluated the clinical, radiological,
pathological features and long-term clinical courses of


















1 improved acute IIP c-NSIP PDN 29 - - alive A
2 improved acute IIP unclassifiable IP PDN + CyA 27 - - alive A
3 improved acute IIP unclassifiable IP PDN + TAC 90 - - alive A
4 improved chronic PM f-NSIP Low-PDN 72 - - alive A
5 improved chronic IIP c-NSIP PDN + TAC 76 - - alive A
6SS improved chronic DM f-NSIP PDN + TAC 19 - - alive A
7 relapsed acute IIP f-NSIP PDN 94 29 PDN alive B
8 relapsed acute PM f-NSIP PDNc 82 61 PDN alive B
9 relapsed acute DM c-NSIP PDNc 70 8 PDN alive B
10 relapsed acute IIP c-NSIP PDNc + CyA 115 46 PDN + CyA alive B
11 relapsed chronic PM f-NSIP PDN + AZA 104 78 PDN alive B
12 deteriorated acute PMb unclassifiable IP PDN + CyA 17 - - dead C
aPatients have received these therapies until ILD relapsed., SS: Sjögren’s syndrome, IIP: idiopathic interstitial pneumonia, PM: polymyositis, DM: dermatomyositis,
bsimultaneous onset of PM and interstitial lung disease, c-NSIP: cellular nonspecific interstitial pneumonia, f-NSIP: fibrosing nonspecific interstitial pneumonia,
IP: interstitial pneumonia, PDN: 0.5 mg/kg/day of prednisone, CyA: cyclosporine A, TAC: tacrolimus, Low-PDN: 0.2 mg/kg/day of prednisone, cstarted with
methylprednisone pulse therapy (500 mg/body), AZA: azathioprine, A: progressive, irreversible disease with potential for stabilization, B: reversible disease with risk
of progression, C: progressive, irreversible disease despite therapy
Table 6 Number of patients of each pathological finding with
moderate or severe grade
Findings acute onset (n= 8) chronic onset (n = 4)
Organizing pneumonia 8 3
Alveolar epithelial injury 6 4
Interstitial cellular infiltration 6 2
Pleural fibrosis 5 3
Collapse 3 4





Fibroblastic focus 0 2
Microscopic honeycombing 0 0
Sasano et al. BMC Pulmonary Medicine  (2016) 16:168 Page 7 of 11
12 patients with EJ-ILD who underwent surgical lung
biopsy. We have shown that patients with EJ-ILD had
often acute onset of ILD with lower-lung predominant
shadows with volume loss on HRCT, pathologically NSIP
or unclassifiable interstitial pneumonia with acute inflam-
matory findings, and good response for initial steroid
therapy, although relapse was frequent among the pa-
tients with corticosteroid monotherapy. In most patients
with EJ-ILD clinical disease behavior was reversible or
progressive and irreversible disease. Although anti-EJ anti-
bodies correlated well with ILD, there are a few reports
which describe the clinical, radiological and pathological
findings of EJ-ILD and no reports describe any detailed
clinical courses [16, 26]. To our knowledge, this is the first
study to describe the detailed clinical features of biopsy-
proven EJ-ILD with long-term follow-up period.
The onset of EJ-ILD was often acute in the present
study. EJ-ILD progressed within three months in previ-
ous literature [15, 16]. Fifty to 70% of patients with anti-
ARS antibodies other than anti-EJ antibody reportedly
presented with chronic onset of ILD [12, 13, 27–29].
This suggests that onset of the disease varies among
ARS-ILD, depending on the type of specific antibody.
Fifty percent of patients in this cohort were ultimately
diagnosed with PM/DM, which was consistent with the
previous report [8, 10]. However, our study showed
that five of six PM/DM patients had ILD-preceding
type, whereas only 30%–35% of patients with anti-ARS
Fig. 6 Changes of pulmonary functions of 10 patients during initial evaluation period. Pulmonary function improved or was stable in nine
patients. a Line graph of forced vital capacity % predicted. b Line graph of diffusing capacity of the lung for carbon monoxide % predicted
Fig. 5 Changes of chest radiographs of patient #11. a The initial chest radiograph before treatment showed infiltration and volume loss of lower
lung field. b After four months from the initiation of treatment, consolidation and volume loss improved. c However they arose again at the time
of relapse. d At the end of follow-up, treatment improved infiltration and volume
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antibodies were reportedly ILD-preceding disease [12, 14,
17, 28].
Regarding to IPAF and anti-synthetase syndrome,
almost no patient presented physical symptoms at initial
visit. However, a half of them developed muscular symp-
toms and fever during follow-up period. This result is also
compatible with the previous report [10]. These suggest
that it is difficult to distinguish anti-synthetase syndrome
from IPAF at initial visit and pulmonary symptoms pre-
cede in some patients with anti-EJ antibody before deve-
loping anti-synthetase syndrome or PM/DM.
The HRCT findings were basically compatible with
those of previous reports on ARS-ILD and ILD associ-
ated with PM/DM [9, 20, 30]. Our study revealed con-
solidation and volume loss along the bronchovascular
bundle predominantly in the middle and lower lung zones.
These findings were similar to the radiological NSIP
pattern [21]. In some cases, changes in lung volume on
chest radiograph correlated well with lung function and
disease condition. Chest radiograph may be an adjunct
indicator when chest CT is unavailable.
Pathologically unclassifiable interstitial pneumonia and
NSIP were observed in our study although recent reports
showed that the histopathological patterns of ARS-ILD
were NSIP, UIP, ALI and DAD [11, 13, 15, 16]. Acute
inflammatory findings have not been shown in ARS-
ILD patients with chronic onset in previous literature
[13, 15, 16]. We here showed that acute inflammatory
findings focally distributed with few hyaline membrane
were observed not only in acute onset but also in chronic
onset. In this point, our results support the recent reports.
The pathological diagnosis of EJ-ILD may not match
but resemble ALI and DAD because these were reported
as indicating the diffuse and uniform widespread invol-
vement of the pulmonary parenchyma and the pulmonary
lobule with hyaline membrane [15, 16, 31, 32]. Moreover,
the high prevalence of acute inflammatory findings
and ILD distribution seem to suggest very similar type
ILD as in other anti-synthetase antibodies. However, we
cannot reliably draw a conclusion because of a small
cohort size.
In this study, the initial treatment response of EJ-ILD
and the rate of relapse were similar to those previously
reported for ARS-ILD [14]. Although the initial treat-
ment for EJ-ILD was effective for most of the patients,
ILD relapsed in nearly half of them. These findings sug-
gest that the patients with EJ-ILD may have the potential
high risk of disease progression. We found that those
with relapse presented with NSIP, often on acute onset
and were on corticosteroid monotherapy in this cohort,
whereas the rate of relapse of ILD was lower in patients
on combination therapy. To date, it has also been shown
Fig. 7 Changes of pulmonary functions of 10 patients during whole follow up period. Four patients deteriorated with corticosteroid monotherapy.
a Line graph of forced vital capacity % predicted. b Line graph of diffusing capacity of the lung for carbon monoxide % predicted
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that in ARS-ILD the corticosteroid dose reduction might
relate to the relapse [12, 14], and combination therapy
of corticosteroid and tacrolimus was effective [33]. The
combination therapy was also recommended to treat
ILD related to PM/DM [34]. These suggest that combi-
nation therapy of corticosteroid and immunosuppressant
may be preferable to corticosteroid monotherapy espe-
cially in case of acute-onset ILD.
This study has several limitations. First, it was a retro-
spective study with a small sample size. Second, since
this study was performed in a specialized single-center
for the respiratory diseases, there might be a selection
bias for the diagnosis of PM/DM at the initial visit.
However, in fact, all patients except patient #12 had
muscle weakness at the initial visit.
Conclusions
We delineated the long-term clinical characteristics of
EJ-ILD. Because of the diversity of the clinical course,
combination therapy of corticosteroid and immunosup-
pressant should be argued on a case-by-case basis to
prevent relapse of EJ-ILD. We need to conduct long-
term observation to assess clinical behavior and prevent
complications of EJ-ILD.
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